U.S. Genomics Expands into Larger Facility with Cummings Properties
WOBURN, Mass. - In conjunction with the launch of its first commercial product, the TrilogyTM platform, and the beginning of its Homeland Security Contract, U.S. Genomics has expanded with Cummings Properties to a new 34,000-square-foot custom-built facility at 12 Gill Street in Woburn.
A significant milestone in U.S. Genomics' progress is the launch of the TrilogyTM platform, the Company's first commercially available product. Currently, U.S. Genomics has more than 20 TrilogyTM-based scientific collaborations in place with leading academic institutions and with diagnostic, pharmaceutical, and biotech companies.
"The expansion to our new, custom-built Cummings facility is especially gratifying" said Stephen P. DeFalco, Chairman and CEO of U.S. Genomics. "We're also happy that our need for growth could be met in the greater Boston area which has an extraordinarily vibrant community for the life sciences industry."
"We are delighted to see U.S. Genomics' growing success, and very pleased to have been able to accommodate their growing specialized scientific needs as they begin commercialization," said Stephen Drohosky of Cummings Properties. "Their new, customized space is the result of a seamless collaboration between our design team, architects, and construction staff, and U.S. Genomics' architects and scientists."
